0001104659-20-060466.txt : 20200513 0001104659-20-060466.hdr.sgml : 20200513 20200513075721 ACCESSION NUMBER: 0001104659-20-060466 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200512 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200513 DATE AS OF CHANGE: 20200513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CANTEL MEDICAL CORP CENTRAL INDEX KEY: 0000019446 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 221760285 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31337 FILM NUMBER: 20871085 BUSINESS ADDRESS: STREET 1: OVERLOOK AT GREAT NOTCH STREET 2: 150 CLOVE ROAD CITY: LITTLE FALLS STATE: NJ ZIP: 07424 BUSINESS PHONE: 973-890-7220 MAIL ADDRESS: STREET 1: OVERLOOK AT GREAT NOTCH STREET 2: 150 CLOVE ROAD CITY: LITTLE FALLS STATE: NJ ZIP: 07424 FORMER COMPANY: FORMER CONFORMED NAME: CANTEL INDUSTRIES INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: STENDIG INDUSTRIES INC DATE OF NAME CHANGE: 19890425 FORMER COMPANY: FORMER CONFORMED NAME: CHARVOZ CARSEN CORP DATE OF NAME CHANGE: 19861215 8-K 1 tm2019508-1_8k.htm FORM 8-K
0000019446 false 0000019446 2020-05-11 2020-05-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) May 12, 2020

 

CANTEL MEDICAL CORP.

(Exact name of registrant as specified in its charter)

 

Delaware   001-31337   22-1760285

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Identification

Number)

 

150 Clove Road, Little Falls, New Jersey   07424
(Address of principal executive offices)   (Zip Code)

 

Registrant's telephone number, including area code: (973) 890-7220

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)  

Name of each exchange on which

registered

Common Stock   CMD   New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

 

 

 

Item 8.01 Other Events.

 

On May 13, 2020, Cantel Medical Corp. (“Cantel” or the “Company”) issued a press release announcing the pricing of $140 million aggregate principal amount of 3.25% convertible senior notes due 2025 (the “Notes”) in a private placement, and the related grant to the initial purchasers of the Notes of an option to purchase up to an additional $28.0 million aggregate principal amount of Notes in the private placement. The pricing occurred on May 12, 2020 and the closing of the private placement offering is expected to occur on May 15, 2020, subject to customary closing conditions.

 

A copy of the press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

This report does not and will not constitute an offer to sell or a solicitation of an offer to buy any securities nor will there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful under the securities laws of such state. Any offer of the Notes will be made only by means of a private offering memorandum.

 

Cautionary Statement Regarding Forward-Looking Statements

 

This report contains “forward-looking statements” as that term is defined under the Private Securities Litigation Reform Act of 1995 and other securities laws. For these statements, we claim the protection of the safe harbor for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on current expectations, estimates, or forecasts about our businesses, the industries in which we operate, and the current beliefs and assumptions of management; they do not relate strictly to historical or current facts. Without limiting the foregoing, words or phrases such as “expect,” “anticipate,” “goal,” “project,” “intend,” “plan,” “believe,” “seek,” “may,” “could,” “aspire,” and variations of such words and similar expressions generally identify forward-looking statements. In addition, any statements that refer to predictions or projections of our future financial performance, anticipated growth, strategic objectives, performance drivers and trends in our businesses, and other characterizations of future events or circumstances are forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions about future events, activities or developments and are subject to numerous risks, uncertainties, and assumptions that are difficult to predict, including the impacts of the COVID-19 pandemic on our operations and financial results, general economic conditions, technological and market changes in the medical device industry, our ability to execute on our strategy, risks associated with operating our international business, including limited operating experience and market recognition in new international markets, changes in United States healthcare policy at both the state and federal level, product liability claims resulting from the use of products we sell and distribute, and risks related to our intellectual property and proprietary rights needed to maintain our competitive position. We caution that undue reliance should not be placed on such forward-looking statements, which speak only as of the date made. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Quarterly Reports on Form 10-Q we have filed or will file hereafter, as further updated by our Current Report on Form 8-K dated May 12, 2020. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

 

Item 9.01     Financial Statements and Exhibits

 

(d) Exhibits

Exhibit 99.1 Press Release, dated May 13, 2020
104.1 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  CANTEL MEDICAL CORP.
   
   
  By: /s/ Shaun M. Blakeman
    Shaun M. Blakemen
    Chief Financial Officer
   

Dated: May 13, 2020

 

 

 EX-99.1 2 tm2019508d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

  

Overlook Corporate Center
150 Clove Rd. – 9th Floor
Little Falls, NJ 07424-2139 USA
www.cantelmedical.com

 

Cantel Announces Pricing of $140 Million Private Offering of Convertible Senior Notes Due 2025

 

Little Falls, New Jersey – (May 13, 2020) - CANTEL MEDICAL CORP. (NYSE:CMD) (“Cantel” or the “Company”) today announced the pricing of its offering of $140 million aggregate principal amount of 3.25% convertible senior notes due 2025 (the “Notes”) in a private offering only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Company also granted the initial purchasers of the Notes an option to purchase, for settlement within a period of 13 days from, and including, the date on which the notes are first issued, up to an additional $28.0 million aggregate principal amount of Notes in the private placement. The issuance and sale of the Notes is scheduled to settle on or about May 15, 2020, subject to customary closing conditions.

 

The Notes will be unsecured, unsubordinated obligations of the Company and will accrue interest at a rate of 3.25% per annum, payable semi-annually in arrears on May 15 and November 15 of each year, commencing on November 15, 2020. The Notes will mature on May 15, 2025, unless earlier repurchased, redeemed or converted. The Notes will be convertible by the noteholders prior to the close of business on the business day immediately preceding February 15, 2025 only under certain circumstances and during certain periods, and irrespective of those circumstances, will be convertible by the noteholders on or after February 15, 2025 until the close of business on the second scheduled trading day immediately preceding May 15, 2025. The initial conversion rate will be 24.0912 shares of the Company’s common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $41.51 per share of the Company’s common stock, which represents a premium of approximately 30% over the last reported sale of $31.93 per share of the Company’s common stock on May 12, 2020), subject to adjustment in certain circumstances. Upon conversion, the Notes may be settled, at the Company’s election, in cash, shares of its common stock (other than cash in lieu of any fractional share) or a combination of cash and shares of its common stock.

 

The Notes will also be redeemable, in whole or in part, for cash at the Company’s option at any time, and from time to time, on or after May 17, 2023 in certain circumstances at a redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, in certain limited circumstances, noteholders may require the Company to repurchase their Notes for cash for a repurchase price equal to the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date.

 

 

 

 

The Company estimates that the net proceeds from this offering will be approximately $135.8 million (or approximately $163.0 million if the initial purchasers exercise in full their option to purchase additional Notes), after deducting the initial purchasers’ discount and before the cost of offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for general corporate purposes, including by applying at least 50% of the amount by which the net proceeds exceeds $100 million to the repayment of debt under the Company’s credit facilities as required by the second amendment to its credit agreement, entered into on May 11, 2020.

 

The Notes and the common stock, if any, issuable upon conversion of the Notes have not been registered under the Securities Act or any applicable state securities laws. As a result, neither the Notes nor the common stock, if any, issuable upon conversion of the Notes may be offered or sold within the United States or to, or for the account or benefit of, U.S. persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state laws.

 

This press release does not and will not constitute an offer to sell or a solicitation of an offer to buy any securities nor will there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful under the securities laws of such state. Any offer of the Notes will be made only by means of a private offering memorandum.

 

About Cantel Medical:

 

Cantel Medical is a leading global company dedicated to delivering innovative infection prevention products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives. Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, instruments and instrument reprocessing workflow systems serving the dental industry, dialysate concentrates, hollow fiber membrane filtration and separation products. Additionally, we provide technical service for our products.

 

For further information, visit www.cantelmedical.com.

 

Contact: Matthew Micowski
  VP, Corporate FP&A and Investor Relations
  mmicowski@cantelmedical.com

 

 

 

 

This press release contains “forward-looking statements” as that term is defined under the Private Securities Litigation Reform Act of 1995 and other securities laws. For these statements, we claim the protection of the safe harbor for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on current expectations, estimates, or forecasts about our businesses, the industries in which we operate, and the current beliefs and assumptions of management; they do not relate strictly to historical or current facts. Without limiting the foregoing, words or phrases such as “expect,” “anticipate,” “goal,” “project,” “intend,” “plan,” “believe,” “seek,” “may,” “could,” “aspire,” and variations of such words and similar expressions generally identify forward-looking statements. In addition, any statements that refer to predictions or projections of our future financial performance, anticipated growth, strategic objectives, performance drivers and trends in our businesses, and other characterizations of future events or circumstances are forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions about future events, activities or developments and are subject to numerous risks, uncertainties, and assumptions that are difficult to predict, including the impacts of the COVID-19 pandemic on our operations and financial results, general economic conditions, technological and market changes in the medical device industry, our ability to execute on our strategy, risks associated with operating our international business, including limited operating experience and market recognition in new international markets, changes in United States healthcare policy at both the state and federal level, product liability claims resulting from the use of products we sell and distribute, and risks related to our intellectual property and proprietary rights needed to maintain our competitive position. We caution that undue reliance should not be placed on such forward-looking statements, which speak only as of the date made. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Quarterly Reports on Form 10-Q we have filed or will file hereafter, as further updated by our Current Report on Form 8-K dated May 12, 2020. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

 

 

 EX-101.SCH 3 cmd-20200512.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cmd-20200512_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 cmd-20200512_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2019508d1_ex99-1img002.jpg GRAPHIC begin 644 tm2019508d1_ex99-1img002.jpg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end XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} JSON 9 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2019508-1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "tm2019508-1_8k.htm" ] }, "labelLink": { "local": [ "cmd-20200512_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "cmd-20200512_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "cmd-20200512.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cmd", "nsuri": "http://cantelmedical.com/20200512", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2019508-1_8k.htm", "contextRef": "From2020-05-11to2020-05-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://cantelmedical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2019508-1_8k.htm", "contextRef": "From2020-05-11to2020-05-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://cantelmedical.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2019508-1_8k.htm cmd-20200512.xsd cmd-20200512_lab.xml cmd-20200512_pre.xml tm2019508d1_ex99-1.htm http://xbrl.sec.gov/dei/2019-01-31 true false ZIP 13 0001104659-20-060466-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-060466-xbrl.zip M4$L#!!0 ( "H_K5!4Y4_^20, )L, 0 8VUD+3(P,C P-3$R+GAS M9+56VW+3,!!]AAG^0?B541RWTT)" M-II[0TO= +4^,8F\2367)E>0FY>M9 M^9*KDTE2\).\.N=H5SHKN_5Y' OR!-IP)=M>4*M[!&2H(BX';>]'EQYUC\_/ M/?+YTYO7!)_66TK)*0<1-_9&Y8_'%8>_& M_DD.QM?P,$SOAJ->%#]VGK\-;[^?)5^[9YT3IN)?=^HR7[)EPB'$C.!)2-/V M9JH;[=>4'OA[]7K@WU]VNAG.RX'-L>#RH0H>-!H-/YLMH4O(<4^+4GK?=],] M9F"BC+-\#9Y+8YD,Y_"1G1!FP0=^/CD'Y970PQS*2V@$"S@#86V@GGR<0'S0 MH/6 [@(1C MK5AT5D"HZZ/4E8C#C-+R%\$S$JF!Z%I^RL:)!H.\K(0. M!@IB 5E!PFS#5&S'F:9222D"Y59--Z_LGEOHDZSKFLX-;<]P=^EY16RHH=_V MT ^T/*+?6%D-;5(BG/*:ILLV?G$SBG5+":;#)96E2P%%5 +:BP1Y>+;6QB::9;I/$= >V2Z+D[9#$VGN[*@NS MBN0&=,K>-(&U7X$5VY"M7TGT05A31EZ8S?(G8_=T,JT=\ID[\,AJWPGY4DDJ M\;+6/-S,*K/,JYSHO-)P7@D.7YC,;HGLG,6<^4*52JN?W6:_W\JUL\3RA4Y5 MMO;+XD_)1E8I2;E-W&_*"QQ;_9>S8QZK_=KRFQ88QW&"+9#LS"XRGF1A;#9)8\]LVT6QH"7&$2*3 24G]K\O*8FR M1/)(2HJ2S$5&([Z'>BD^(:D/4A]_VFU2]$)XEC#Z:30].AXA0B,6)W3]:?1U M,;Y8S.;S$C^OLWW,\^?SR>3U]?6(LA?\ROA3=A2Q8=DM]^1 MDP>[F93SB8R?4++&.8GE@<[D@:9_EP?ZKMI]C5.=%6+(E&Y/_%=FY:?O/IM9_75.Z\%ELMBV27B^Z+Q,JDS**C!2Z.4'0,5=YU M[BQJY9O*UIQQL^R9R+?(,R/1T9J]3&*2B+RG9W)C+#?&Q].JQ?Y.[/ICQL1@ MX&*5Y1Q'N]12Q4DPB)CJHYWRS#'_@;&,] M;%5V9DG\(UW5\>7)$8< C+9DG&1LRR/RIKIINH7.4N5HDPJ%'%41.OZZ&/U8 M:-#O2O6?CY-#+LZJ6PR'MAM"\Z7(UU*.=K*KRK:94G7=3 NBJBV&])I6$B0U M7JKY0AP^EA:N4KRV%$)+=U715ENJIEN)052US9%>U[4&29'?ROY"LH@GSW*8 MWU6:ELQYU5M,&@0T-&&!8!J#>6AHO3;U]V2=R"Y'&I%7OT3N[&C8 +WKSJ#3 MMMX[6,5!H#/$(=A_-(-0'>65I@M*MSB])\^,=T'4EKEFQV921Z:I"8H4BS$0 MD%*+2K%7+OZQ%=?VA*?[7C0,I6LZ *LZ()HL*$;LWD!,:GD(I"PYIEDBF[1> M5$RI\TL2P*QQ>:+I@J(%, =?MM3Z$'A9/)(TE8\0,.UO7&QBU\S AG5J3&50 MW(#V0'**"%2%A ;/Y8LJH&,*@<('<@]P'P1+G3WH[3%;/_,%=$'@ MTF/.>!).V3+FF>Y'OYLM[-=K,BW%)$4^**$,B<(D-/#X((P)1.0BE# M4H=*HK?(]-ANDP.( M P*HVR' D0A"[2C_.,UIQ/@S:[Q.,6-;T23N9RR&1RX]46[1&E2$-F"=(0%A M-L0G %LK]$/YS@MB<@I1D0&2.7CD[B*.Q>G*JG^N$TJFX%FP:MTRUF&W399% M&!!/L#N HDKY06T@&8-N:5CHG+RAP"?^T3D9BLY)T.B=Y2L+"IW3-Q3X MU#\ZIT/1.0T:G=-WH2.J/X!V9R8V;_F2O=I>#0>57L QK5JQ., M#)#C'!GB'Y9BV'7+[SA[26@$#Z@AN1=L --6=C1M> #9#?915 ^759Q_E*J! M>^\?C)+Y:7':)NW-3:D)#Y6VL=Z&IE3[!^..93E._YT\=UZRV\5>(+$:MJ+2 M4H8'C,U>'S9E#!)!_B[!*W3E@Q'K!#.<% Z]!.=E;5%E-U33?2PJAHTY!1S\7?N-#X^Z.6Z]*D=X^,PJ\> MF!)7]0V94W6NIP=1[X IO>X+&2IT7N_GRQ4R,GN#WDASUN/K=NH.7B4$4<>Z M&Z/[5NE>ZO0WGN3B^#.VV6QI]G(B(!QU(A 90@J8D* 9YYE M6\+?A) EQ!-(H'D )T,?(E20R5ZTRD#_A"U(M!7]YGYZLEHF>6J[##4ESGHI MP%S=1VGI01 "F-*)*-(0>T#3D[^N_H94E!<(;MB28[DZ[F*_6;$46$_+JG*% M0H=%18-%$@00L"^=B1N&*BDJM?[6VVI9MA1*2W>%@=66 J"5&$35VQP9#4&K MQKUV I>[Z%%8(\#4"+O,=6=@,ZEW"$U-$"!T&#,N7"HI4EI_4R,.7=FZ?W"P M]C8X6/<,#M8A#@[60P<':\^# W7PQ@)O\0 '?%"ZNQ(:EK(#.V>J=73;KY3MMHB!(Z7)F M+.!9+JG7$".I]D/'-DYR$I>6KA**:93@M%X(TG9/O3_$&3,#S=?X].C#(&F8 M20.J,DRMUU@''A;U]',SOGS-XS>2IK]0]DH7!&>,DKB\ V-[[M2M=_M>3H_M M]JLY@#@(J(8X!%[0D4'C)QF%5%AU_\PC3]]8NJ4YYL7\=VYKI0"=6WX FVUN M-%% O-B= 9S48E2J?4XG+U>_J(=@Y1>9P&)"3RSM-:W/,K=J R.DT",TX MK]8L.8R5[XAL_$0&S-.MY4UU3NE[\Q+)HKX-22@""Q^>I8!X"N25.Y)<)JL4U$2Q(0$39? !&%%"FM1R(N-X2O1;?W,V>O^6.U M*BU80D#MEI!.RVU2K-* B.GR!Y"C0E 9HQ82]HG0[K"P>KF>)%Q>B]0Q/*!9 MC1Q#%Q(VD#F#F91$\O[,#?[FBOBE_GX_09+%,D)&N7( MG<:8VT#J$CO_'@MHV/@JBZ$, J=>>_ 76NH(I$*\L',K>.;-*[["RCPG&W#> M17^(*XZ&FEF#8&J@29VL(JQ]&5X$(AGI?V6FYE+_\ "P)7(\;K88U(;- M#440I("VH$%S\\L)/E<&W*[2)+I*&8;ORK0TCM<#-.UI2P$>! %Q8+J"%@ L MA*A0>J3@,Z9/?/N<1_L[SB)"Y!M=6=U^]=VU&QCMEIPW%:G-U*#0@&A[BU^ MPT,6J)''AT8?YO\6H'QQ7:Y5QZ*GQ2,6I_%VFV>R9Q7VX/OHG4&.'U ,*(#V MF*(C(B !]B$'ED4D:@(_8#*8-2(]GH-EQU6.B3QY_T]>2!,J9$"LZRN\P<71+_AZ X- \:UNH\ M$,D3:,.5O&QUCHY;"J2SMRY%ZDWQB!9PG[T&"9E;I-\D7)DI_1/6X )UT53$5 M8,%]L6SX/'E]=#I,TA11[1>0N=*?[_N;:B?63L_;[=EL=B35$YLI_6B.,H6K M;F"9+IG6?Q";03:!@J5<>F@9M-:E?"UUY3IG9V?MZMNUZ8'E?*C%NHW3]MJ=3C,F:KF#5ZY+.W:KL1,/HLI45N6O!M?&Z<^+K?[5C M8Q=3US,-]QVKE;1WVIYJ,"!M)??&'=@I G/K.A3DZXI\\\_RSG+K2ZQZ32=) M?1@^[BT7'FS]D>H;,<%X4.A]N1Z#XQSH0)N(#L:JZ=V#MR![YSY#ZG_ MD!YW5KA?N4/?JN:NAL9JEMEU?8(-052M?',V>R;M'^;;FLJ#J[?>M5V+?<^V MHWBELT3I'+3COJZ+Z6PG=H>]=671GC+M*DJS"1>;L(^T*D*,5CQ4P-%M7*Z) M'\GTRGF1>T]Z@HWKH>Z9(*EV*+#6JJ'E^@Y,IOG4TVG NV.)I'Q"2KE&&PGL M]=ET#V/NO?8.^:LR^(/QD2)0!(G_E'+LB*HEC<.5E"43]S!5N@'_KB62^J^4 MU.NTD<+^NV3:@A8+#.\#8R3RUY3( PI)J3]H)@WWE##8#ZV1W'\CO3D):"0% M/YB $#[]8Q+5X^OLD?!_IX0?UOEB\%\_^7L =^'!1V"K"#((?[R4(!RH)8W# M'6BN. MF3CT&G,L>))\M5'F"X#_+S"-1K]EC 5/DL(V2"3!WBVUWG$I.LZ$K;'@29+7 M)I$DY*^EY7;A9Q8^E<7P^X/97>*'5EC2) EK2!0AX?43"VG]S$F,\KXEEC1) MGAH31TB[ZU1I)OHRA_D'6,1P'YAB>9/DIU%YA,#O-"^87@QXUCR,'-IBD9-D MI7&!A,P?V+R?.VU\Q)>SD&+KHJ MCP[U#06Q02')59\AG3 T5WGNH)G5GQLNH1,+2*TY>CZ*+@P1F2\*_LGSX)_@ MX9/DL(TR7Q3\T^?!/\7#)\EC&V72P^^ZC[?Z0P/2F #0)C>QL721V%U(X#I^6M++'7"5+=>'#WM.V4L$__Q M:=,]9[T]ECQATAL32O/09*!E]TGMHA:5+DH6&1-$,R'XUM D.!EM?H]?8D0RW^S)( M8'[5W#H_NJHH2KEZXA.8APN88B&3I(Y1>23 !TKPC%LNQQ_=':7F3-33KK/# MHB9)%,/"2#C?:?!1!W>S7JTT\QLH].UH%!J18_98[B1Y8K/0E\"_;TP)^KE1 MJ"F%C05)RH@533/R0%:ZX7#1.1D^^/U @7'GP I+G"1=#(DB(?Q)/6CF=R4. M%L50B?"&EUI#+&>2Y# BC03UCC?UD/=,L'A)LL):.:2CQ/4\FS YAO ZBGI+ M+&:2+#$FCGA,'J/&Y/$SQV22;#$DBI3PO\0)?>( M5)J=BM6&)K^A71>5-SWWH1Y^P!2+G69+:$P>#? RYQ;RI6,]+IG,7#JVV<$7 MR.^;2V'#0+-G%"F:+5W7@? B88L$3SED&Y%&N%%TNRMYZ]5C,[6>UHC2$/%,"B)UR- M&Y5*&8+Y]_WTRYU^4?XUUNAW-1#"#XJD?2%)EOF%'4#!U44?JN4RAX'$R?=W):V>C^L\S+ZV"%:#AL@RDVK".&D M=TKF^V8VR-\N[F$$VB^8>("Y?>N:>XS?."&*8Z-$^O8E-(::8%VT#W3=N /^ M5<#+;_PO_[I;=^1_4$L#!!0 ( "H_K5#"4]%"WQ< $!V 2 =&TR M,#$Y-3 X+3%?.&LN:'1M[3UK=]JZLM^S5OZ#+O?L<]-U A@(24A:SB*0I#3/ M0M)F]TN6L 4H\:N6':"__LY(MK'!Y%62-CVG>[<)EC0:S7M&LGC_[[%EDCOF M">[8'W*E@I8CS-8=@]N##[G [^>W<_^NKZZ\'_K0#_K:XD-NZ/ON3K$X&HT* MHTK!\0;%4JU6*XZQ3TYUVAEG]BMK6JEX=7+,%_4M(=O>S^T^[%GV/VJ+O>!;U@8<(J9K7ROGR9@)(7C ] M!0@^%P;.W8-PMO.54@1GCCGIE6)SCXJ8X@:;(7*R6@>ZR_$/AF M$5JCCH'(#RAUX\Y]*GJR8]B0 1M:/,=D(G.,;,D8I#N![7N3[#6$C3AL*SU, M>/[\-/ P:P;+B+OJU/:9:3&#Z]0LZ(X%_5'@2N6<5#]&#?A)\,][G_LFJ[\O MJI_0:C&?$@249]\#?OR0+O-WR2FUV X9&^-=TF[)7ZZUO2=6@\%$QX]!08 MY>OND'I,7)>OI:U40(1\]A0X+<3E/(15F4-I(?">8TR(\"K ,"'N]+43?X733.X,(UZ62'V([-9",?[Z#4,D\J M@_S(#8/9H6[@ ^A[&E@ 3E>"/_8[:%H./,="<)],37%S\VKK.V''%CHG9X#=HC:4E:2&*5$*5>7[0N0**;)@4B! MW60>.'0FHDYHIG>$]+^ 'Y%.=68D8I(3LA30@W[J5)9.2B84PR)'X:/^<&MO0Y\XA<#,MT;\WV M49IYLX.GTQ4SYPMG5I],;J2'1 M\Q0"T<.0I&DZ!S971 ;EG*.FQ:@(/%8/M7@'^D3 HJ;T% AM 7QE$A9.$1)! M=GKV'%/3,SHD$70XIQ&*C,1&='W10 !/_&_]VYD>"WJ#;B]0[0=UPP]V47?$KXI.?XOF/MD H^&W'#'Z(_T/[*I8;W' ^P M4L/W3*K?$H!!A&-R8Y>$C1$DU5Z:MJ.3R0O^ UP8/,W5__F_I4UM5ZTO_#>Q MA&)J#0M7'P%Q9[J$'FW[(8\6$0" 05=MEZ#"YJG)!_!(!V/#/"!!KWYYVK[8 M;Y'N1>-BO_N^V*N__)3=_>9EIWW1WN^2QFF+[%\U/S9.#_=)\^SDI-WMML]. M[\7C06?^6#R^-KH?VZ>'%V>GZZ15:!9(6:MNU%YA[M?B[<%9YR2<2[C4EH8- M8ZN:MBE#QGR^Y>@!NG@,UZ_U.+J-P]OK'RUF'MXV+B>?+B!(^NDH)SE?KKZ= M/YH-*-X7$=-ZD@F_CA%+DS20]\[^Z07I[)^?=2Y>1[K/ T\$D/80WX&!.J;6 M:KFE"G$\4JJN&>_4 Z>_NN(/&?8*/.YSF'M_K ^I#2:JH?O$Z9-2K;+QZQ5C M2;21NO#D! &C(R1%A[F.YY,U_+RZ @\8!=?'A$_8')62>2M4Z;, %EJY\S%ZS>6>6+[SF5K^_-Z9+ M,)Y9\^;JS<;IQ?XQ.=EOM9N-8W"BG?,%'"J\@@:O[8\IF Q$&I7%BY$E5!#A M,AV3'X-P>W6%^X* E0%=\=Z]KL3XM&YHG* ::L_FLJ6X\9GF)I^<59VDRQ](";#-;? M8UXV_\[-[Y>;9>O+#^UF:<9J.B=60[ $7:EL_6WJ(_D$_WA/LFF9=':S,GEM+HW7GLV2 M-6D=,/1U(-CUR W$NL+@,C!.Q2WDF7]>?@G@4'G2WKU+X/T4E7F&GOPBGC4= MR^)"O!T6H<$C2I7^?.ZT.UV2-B)OA$L+&!19LJ(,$.M+"$?_@-"S^O*NL9IR MC0W#\)@0X8]C;K-2MEOL5;Z8P_V#S6YC>0%+QN2Y>JFJD:;IW#%8$346N,5U MD&9 M?))N]KE!-H*@_2":GY@GV.0WC$0WMEY< MW6I9;#QW@)[F-^XN3O"J TU43]MGV\.EZUMJ=D@5MC;*&T]CSE*"T&?ZP7 1 M6/!P/9 Q[E*3L#'3 Y_?81T$W",3[YXA4LN*!9ZY,& (08Z\RXCWDW[R;1>$ MIQ6U_Q/0P63NT+$9L660L(XAMQF@:R;48Q0DW0"7^BR*+JPTKBU*%M%D-V#6 MQ4KI3DSM6[]UJ+-EY(;)^7+UVE9E@1*^F_,-D5$Y=D @SY& ]V6TET/3/=-9 M[< K+P'KV3ES]>V:EM\J/[Y6_9;%]U4F63L [PM9LRKL>M(9PT>J+!\H29^H M'2-C=46@FR4F%=%FR"N7=W\^:&\.F7Y+<$^,NA!A@%''TD'/&9,>,YT1KA8; MD29J[NW\$>ES$XS$Z@H78#)\9AO,P+TWP:W ]*G-G$"8$R(@3Q+]B1RO1A"G M!\N1Z1-Z$&Q(E,T#@ -TMB=16Q^">6>$XS#VX9@;BYTEKGUAPI),4&83F)]+ M6%)I7L;9#0U/58!KO\?OJ=0F]HPA>*U0KG([P__E^]3BYF2'?(45X*I$;BY, M.@@MVE4*UH!.KZ;1@E+ MC1#^0T0S1').,)\IO5W'Y#KPRAZ<@ T#0V9FBVYS?%S^MEWACWDXM!8RFUL,=*\1QVKR/+ M%9;?6-.?*LOAJ%>3Y9\'F(B)5/3./(C_W86'\*8*'AV_ TJ\2AS_ZS8>'M#2 MF>K6_)GLQ)GKA\YDA^TFZ_L9K>&2PV:MH&US>Y?\WEV*K8^6>1^A/]X/8F8/=JP;(F(\MS0=2C/D2T. MH^['O6,M<&_8\W/;J3BD)@19.&F]+1'P^&"8Q>,_3D(V9VQ&E! 'VG- MUJE]+ISGVXW9HQ3H(N=/463AI$Y/_.UXM\JRQ(G<$P^+ON 1JY\'V+;QG@C< M\9D076X%08=;"!Z8/#DZLT/#!0&60DZ,, :K*P//&?E#3(]=W+:A@ABLSVWY MUD.RI*Y5HRV=F7JZ>M^J0M:PX]:N+*M'G;E\9\+%=R9P&RZ1:)=[^3)YY*M< M,6C,M<.!:>"%E\M$?Q[@,]5O/V01F>%0))^/+P4]L5Z4/C<5H7$HL6@J)+)U M_6;<^-9K\KTO5N]%2T7W(/;$ZOP?)S1MT*B$>L_(#IX.R;05?&XC=PB&@)E, M]\$0V(ZL" 6"R5[ QG"[&&]"XG(G6-V[@-Q;7<')S G./N(P-\JL#?B"_GOL MC@L8"/:%VCKN@5!=WA"$G?$>*H-ZAE [Q<:]]:C*&HWK47,5N@):[,-+$NY^O4B\ 3H.Q#&P#:P:. MMX/%%Y\]YWBZ')A'5!G>R#3RJ#M?C4H>HMTNN>.?B=+;/HL.]A2TTL(UD1-U M81MI.IY;P*!UNUS6=E6C_%#:12^([BIJ4WXY;'P'P;D(P.]1<(%X0M<##TS! MZU+;!LE$R9>#78AH9.P.ON\?I0V-@$LST0O3P0!<.+KWZ<%>:J&#Q8@YY%FE M4*[^-7\B-&5M(%J3 HMZ)YC- 6L( H H1L!PS56R!HBLKH3+.,6VZ2)LN0!^ M)Q$!$RHWX-9A%48899@4PXJ!%[IV?,AM""34H0APY()Y(DHW)'#\ /@ZKHPV M8$S4;W4EFVXZ0G;L9X-#GO5!C* +I"]L[*H("Q8@0<=PJY%HB:!W WVPAQX(L-G4 MF\2S )O4DE$I7^0N@QF->16U;,"ZW,F4A$E- *+U&"Z]STT\O$DQ8QSR'O=) MK58H*6F"3DUD$_ WO/X"R)HZ_:A^0:;)XX_12XK ";!S !_#X_C*MN4EE[^0 MJ!=(%76^E1@. ,.@'@DP B61'T"8!.15 =X3@JJ&AD$2.CH/R#B8ZD#51B(\%"S9'[GZ L _ MG*1 &O*<*JX@96L0Z=45 M@&A1 _=AS G*@P6IJ+)#L5K'NFPQ"^3'-@+KC0G+C!.4,QI,#]_8W5&DQ*MO M<_4F#:1U!?LCWU&RE'X-(&5#$H!^C>#7_+'CW,I]QZB/^(-,T^)\\J'=6%"_ MU950_[ 60CD(4^@^^R'IS)!T(B9=%#6 F?.'%+P \RPT65&);BKIYZ%()DII MQ_ C/*C=P;3 6EV)BVJUJE1^]6[YC)84D)>1?L:HK),1NC?*K= L@ZKHR5/@ M@O89&5*OI\[;D\6KPA*!I( J,H:9/2EO-1XH,2+*<>_2?D;OK/*A=.&IM8"! M0X-$A?+D>N@LE#M6!X36"0-KB&U&J93X0M">TX L,%9]P+PPN"=L(N* M80QPT5YHS)3Y J(Y+EZ'R*8!4#@?FAB3L[Z0#11"/\M5AY, <9 A2*T0VUT< M,P&C+:VT"IX(3J/[8)C ]()H^8XG(T] -%I,G^H0JY.OW!\BOB:WU/%3=2@? MXB$'/JVOKHP<++G 0'?H 4&$,I T%DY%E/5($L.G$+EQ#*1@63,M X>:L\] M6&XR@*CW#J*G<30)P9(]VU52ZFYN,L'8[>PSBTYF'^GH(N:6(%SN32$"#U97 M[BB^.Q'Q0%)"T0*0$58!UU%J MX/. Z\21426_0]%-#%M=,<".8/ M914$R9"R/"OM4]N!5R*!I(&5^S$E7(B9 MO&%,8J]S3P\L==.\P!?3[J/2ZDI'WKJI.NK*[6"0+"V@5.7%H^48Z;*3!%0Z MFT(+%H$$4&8#4#3@L>FXD7U C82^B?#;QE*R$T 4Q<4M#(>$#%(DL&((87U. MAR6V",+@^$)E8/H)KB9?TY.6 ]) W8]3GN;9EW8K7ZJMKH"[,9B%#%-,4+9$ MK0I) 71(*AL&5/$ MD&8FUN4#5'@/Z>)/9'_UYA?S,4"3&](0@3,6OM9EH9S24).Q0,\@U,>W?5U' M5?#!4\2ZIF078HN R?DYJBT10QEHHQ/JA1FM])[22BY6R/4HCG<9O56:26-! MQ]O]9)2M8@X**NI)LV(",91)-IC0/>XF(@W!$O8'- ="*BPDA!)G&VG-5(L! MIT H1.NZGS2=4VT"V\B8;+(<^2(@%F&#)YT#>*@>$4?.(Y$2?H?_JRI#>L7#&**G"3S);I7T8 M'%^" +2-:*AF,#!WP85EI\0$WP54_9(%#2D.H:,S)\ %+E3L)U_M2[P!Z*D8 MU*>2[2!I4:;N!M!+-U56J% 1\1Z0LI".;+O'EL=A(E! Y>5R@C[*OQP;$CF4 MZV3\ICCCR?1$):"H0-[,J,@53&WDO+>*SN&A4Y@DTD>9_V ] L/(ET[[L@OC M+[#-^-B$)BP[KZ[4"EJ))$K""LWY?_&"W]A;=1/^6FJ++.&()2]NZ;GR&EZ3 MRNM3=/DK;U(LYZJCV*2'C*$N#*S5!(1-JXN.S@]?YOZ1J&;+^=O-9<[7U]#[@7NKZY\M7J2E;]2A67.NFS.48 H17$ MZT(FQM/:/I;B(5:'E:KH'*\M[K$A-?L8!\H=_L\^_0N@T9)_R)4S+[0NS%CW)=Z)[>A%9KEX41=(=TL F)P7L>2L3Z8A]9F\MLM[5=%8IMO'F_O!AZ7CI9>R0?<$%>5=#OD&"\%^FUB MC!?Q](GC^]:'@A5.?WT"_/8I_'!C:$=C6X:)\-O MM<'6>&_S^.K$.#IVMCYV/7ZP=\LK)KWJ7AUX'=^K;FO\7^[5EU:K??C9_OC# M;K;V/Q^5O._-H7FV_6/2:M2^G;J=Z%H?M[]^=MQQ\_2V/#@2FUK[SG:/7/_S MP>%WX\N>[ER*0^/[UZ/3B^*98[0"]],P<*_,2F??=[^?^*/@YLJNMCZ>W/YM MV)VKUK^.>L/N^+AST7*.A@W/]7K5L7?Q]?)S^;AI!?UO5W=:97O_8UF,/QTT M/GQ0)/E_4$L#!!0 ( "H_K5 A)#2C(!$ !] 6 =&TR,#$Y-3 X M9#%?97@Y.2TQ+FAT;>U<^U,;Q[+^G2K^A[F4[7*JA)!X).81U\4\C\]??K[EEI)80##M2U4TFY$-J=1W=/]]>/:;+WC^N/ MI^^7E_;^<;1_B$]%_^U=GUR?'KW?6Y-/O%T+K_<^G!_^IJZN?SL]^GFEGV?E MCNIVBE)=V]1X=69&ZC)/==:2!RUU99SMKV BIEX\==ZN2K4;V&Q'=5;>O\EZ MOMC=6[N86ZPT=^6J3NP PYP=#,M=]57K[WUX?W0WM#U;JNWM=G?O^/SLNDGP M:E^G-AGO_-&2/-;;_QBA NOT5+X^/#^/O5?02J&$KG/1E\M6*;R(2E_/9WU M4M?['TZ/U,'1Z>G5Q?[!R=DO/Z]T5OC[Q?[A8?W]R=N-;%P.:6CG]:[JY2XV M;C7*DT07'AS6OY$&[EU?ULO?&E?:2">UWO3RLLS3E:#^>]>'ZO+\WR#S[.>5 MS95%BI:8?CG9^Z=WK^^)=5?-[U'F!:1Q\O$7=75Y@-72]4YW>ZOS+N[^K[G; MWE[MVG30Z:RW/Q>#%;5_>OWS"@GO^K!!5" D;+N^?G_;Y]2+W=@6,CY=[7_[ M7 !G1Z-1.]+0HB0U,='3CO)4\/$^]6L,'(PAWS)P/AMD\L\M0I FX$1L=(NH MGY/M 6D_R_(JB[#MA;.1S08J[ZM7WS[O]T&&##C( M,]:1'O3LRF0V=^HL+['(8674>F=]:^:4GHGCK^2T%O\S$K0*D&:B)@\XHM@A M&L,#,9DP:-XE/()J,>+EI=J*0= _C?-F3(S4**7>?M1CU=UHD[ M?W9]=*H^'AV>'.R?JH/SRPN:TU9OSWZ[.MHY^'CX@WK[)HE_K_)=T8(WCK\H MG&(Y-*I^EZ>%SL;AY0_+2V4>8S<=%";FL<54:6SI\3'5$5:B-"B1'@R<&9 : M8486V4(G2J=8J*2A&^WUK==PPE.E\J)4&2M5')1J>>EM@SY6N)HZ9;$'K:6V,CQN_J]POGT+;[;S)>VK$J0#2)[ MU1AS55$Y7T%8) 5U68'"[N;FOJHRQ!$LB"L35!DCZ!DA+A2#D4<4%(>@.2,I1$D50X8M7C]F ML69J-+31$$+ (SD;[8SJ6^=+9;VO3-Q254&[@Q0=QS9(\=7ZN_9CE4%8 8%! MO_A$BT1'3#V+:'F)-M/00J;5Z\3,"L)ZY:.AB7%0?,#"/3$ 4>A>7I6*+6=+ M+*>E?-7[;'!N&!M5'I:KW5A%2>Y)BZ"8PHEOOPR*MSOW@/PSJ+#]\1\AQ3/[ MEI<&-CX[.:(1E($,K\H\V0)K3H9C0&AN,TTJG_>PL&:YUZ<[,0V<.B^@H\A5 M9!GP!09*J/%/.<& "O0<@*M"HI=Z#%L'R1XD]I5>@AT'3-V.$ #F5,6%(.W M.$-4F/8P']^QGM'14(TQK@652*&- GU9Q Q>CK 4JDTO M2*DA ;#3JZ#=M'DNMC;Y3C!O4XJY($C(IW &>$^\'IN>J\@T:@8$804&(Y"@ M(WEI<8:2!Z7\#X[&VP8A XNTCKL9P& ^]# M&Q;0"H"QR1\( G;#,*\JI?FS.VQT7BN8 MBGC,1'NX4TS,2:TG(/YJH]O>WG@:%1.S70^1T R@ZYC E%T?:>41G[74]'PI.IHA^6V.-4@26@;# MIV4*&%"QV(!Q?:>CX#YYF1]8M6F1'@$DG21&TE1Q@@]N];?3>EZGQ7$9]$'@ MF1P*G_@((&3HC CAM"LE[I+S6:PP(58CGX7S+L&:Q%X4A?%7QFQZ#*AJ(!NK M^D^LZAL/JG1PA: QE6W$[ T%NK4O6 0D4[4O&UQ"[1%V)I4/'C=F0JNLT#:> M>%^(@547MI.W@*RE,G8'FIB?5DE8[P M#AC1C U ]M2+TAM;)Z>3\^BS)35&/4XV$O?."J?AKO^T> "6B8U(H9JTL:3^ MXB;\3%3-T_-?JZOJV)HDWE$7>F!VL>GO%<(VFJ!65^MZUN')K_62343IKC<@ MI4:0'^E9J!_7SSX@.;E17=#N\\3&H.-B=CUFKWDUL;>&/1=L7X#*U1Y"T9O5 MGH&6@E"=C)"9S6+=CPL((VJ?NG-#/FLD()')-W"0WZ.'J/$'EL[QCB??+L"? MF1)XDD?&Q#Z@^] VJB5U7#@7CW4WMMKO)EGS6P*MN0$_;K0[RTOU"-MOE@E4 MHTI@[HR+K*=WJE\E28#%^\6"9M+.0(=02IQ.C'@8\0BH?: 4$=R:BJV/&# ) M D6+)>;./3N8"=?FKC!(_GR=EM4!?1#D;#&$0#2+&7T Y?[[J M=J:%CN!* .9ZS/$GEHM-KVS4C>Z%M?"1ME1]'=E$ZD/:UVXN#A*B_)6S%*XL MI2'8Y[!/9NN!,UPM:2FNDG)5"T/J,+D;LM27K=#^A6V]+K?%0;.;"5'MY+E$ M16I=S686LT'64-]R"@M+,<@2S$9/$5PX+9:9OR4Q:ZE/[JEW7;5ML7M" F3(L$B?@6H@GI7(IT;>F MI#WSDCZQ<*?98!V(DIR=9%'!NE+.7L/AS,F<3GI>WLM++.5O+0;Z[LS)>G@1 M1R489PAX$?'FK)WEM,Q'7Z""4I@W7._D!HM==(%UR"I2>'[ MLKA*_X;\K\PL/KS?IVL#A'E\9:8^RHWTSLM?='Y_,GV,W<^*D2YTH+@P?P[' M!DG>XYA-8K^8!Y5RE1.;Q-Z*6MLLRZ'H5#>V65^*;U1\O 62RZ\YQ:SBJ!&B MWMHH5 $*S"*X;ZE(DR\@WQ;*T5*6&QJ=E$-Z2:O<6JXXB,7;E)[ NJH2!)+@ M3#;DNRBO^Z:4RXFA20I\QS"BUK?E=,XK-R5*HD_,*DR$4!JRB1'*BSS )1'+ M954$F)ZOH?P8H4$J#"#NRQ%F%[*;,Q2OQUAE["T(TO&MYBO:D:;0'5[3]DF" M)!1R=H7$AA1IV$2S'!"UBPSIJT@BPG%D))@PT!)OB H<,XN0P98YG\.$):)L MF/L"&)B$RC\VHI-,D#!$L@V";W:BTR,#LIUM]G)3C*W4T_R4<34;)2A)0F[&(!DY@]ACJ(0 E) M02'U&U#^@.V&>4*+]"U=^0!;>Y (W8(F=40A^E;H\+7F"X ^R:X2A%BCB7+! M?*)AQB(Y!)9JJ23>0IE+M;!]Z%N6 MXK3UL=GJ.-\*&=9\L(=QKM?Q*Z+38W6<$.4'*A:3,J4N3 MR#7X]\9\%;7POV+OW,9)N!,X+ MJ'B<:5'>K&;39@JC-$*?NL<,ISW2+EZEYFR.'RFIY""I;OC3=8W:N)1ZIF+3 MM]E,[:EN_FS40T[Q(6TY "9RNM.&MVUIFY$0^EXYZE@*/MXT*.$@*$JT3<.E M&Q+J%B]#!3-?]<["2">9GUG_8?J.F$%CVF>#*Z>[1@]-%= MA ?RCR=MLG5Z1E6N!6N1U>!5&?%9$?Q)Q6Y(RD)4*90WPW4%3 3:4]3N26- MHKVZ'X6&2*&=P]%0@) ,!"++"T,.HS6M08;]N*VQ+V$P!>M2'N/" +0(%DFT M[M(4Y%4Y%U8YI*$G>BDB:=5*&)["05BZ;P53/Y11$6=>QP@\7'3%>D$;I'$3#O86 XB M'%:XKJ"F-\A&$DE_0^+G[\TEU2M21+=N94 KZ&8@"J1P M4O'91!/*2//Z%;>H 0&0W_']D7$<4\.[T>+U\<1JX/)12=TMG! -;*1R+J]2 MIMMJ3E.QX]1:M-3Q!0ZT>%[/IY@!.Z.N%T#8Y7&!KBD^,=88J\$#L"UQPQGIKDKR89J2T4*,E M*4-RZO(*V&W]C:LTTZ)Z4%<"-N0/@2I,QO0FZA7$L(A)''EE6/[I; MJ*FG_LO*28N%-$5QS[;H5E,R=4?)=![!$'"U;B(.U .1\T'&3!('&?SO[.*3 MHD.#S]DKCF;MB"K"8[I2A,\?BD/C^C%+W,0LWH24I57G^:"TE@K[11_.@R\T MY8[3\!4HSG=2>!D9J8-SR85N-FROJKV#R$] GBMHM< 2ZE>CCANJ $3IRU"&\I&S M12.P\*8!.S"9W%'EJU8V;MYIF*2P0G==ND]5JR9@3NT(B&@,OTKIKIL:1+'D M/K<9 X9H#V+UF&*F;F?U?ZAD5.OS7,A!%$S"CH,5Y:A!M4.5FE";G07^@X&*Y&R*;<7.S:MR? M0N)]SU3_O81XYLF]CG2B>HD5'ZY'+2@K/?U/EI^:?#REUO?_3^ 3^KTV=M6Y M>-,==4K='=],LOZ<*?/"(WD!0:_1G_?+W_O+_Q;@_P!02P$"% ,4 " J M/ZU05.5/_DD# ";# $ @ $ 8VUD+3(P,C P-3$R M+GAS9%!+ 0(4 Q0 ( "H_K5!50AJH_0H -^' 4 " M 7<# !C;60M,C R,# U,3)?;&%B+GAM;%!+ 0(4 Q0 ( "H_K5!42.O6 M6@< #U9 4 " :8. !C;60M,C R,# U,3)?<')E+GAM M;%!+ 0(4 Q0 ( "H_K5#"4]%"WQ< $!V 2 " 3(6 M !T;3(P,3DU,#@M,5\X:RYH=&U02P$"% ,4 " J/ZU0(20THR 1 ? M0 %@ @ %!+@ =&TR,#$Y-3 X9#%?97@Y.2TQ+FAT;5!+ 4!08 !0 % $8! "5/P ! end XML 14 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover
May 12, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 12, 2020
Entity File Number 001-31337
Entity Registrant Name CANTEL MEDICAL CORP
Entity Central Index Key 0000019446
Entity Tax Identification Number 22-1760285
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 150 Clove Road
Entity Address, City or Town Little Falls
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07424
City Area Code 973
Local Phone Number 890-7220
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol CMD
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 15 tm2019508-1_8k_htm.xml IDEA: XBRL DOCUMENT 0000019446 2020-05-11 2020-05-12 iso4217:USD shares iso4217:USD shares 0000019446 false 8-K 2020-05-12 CANTEL MEDICAL CORP DE 001-31337 22-1760285 150 Clove Road Little Falls NJ 07424 973 890-7220 false false false false Common Stock CMD NYSE false